Clinical Drug Resistance Linked to Inter-Convertible Phenotypic and Functional States of Tumor-Propagating Cells in Multiple Myeloma

Aristeidis Chaidos1,2*, Chris P Bames3*, Gillian Cowan2*, Philippa May1*, Valeria Melo1*, Evdoxia Hatjiharissi4, Maria Papaioannou2,5*, Heather Harrington6*, Helen Doolittle2*, Evangelos Terpos7, Meletios A Dimopoulos7, Saad Abdalla1,2*, Helen Yarranton8*, Kikkeri Naresh2,9*, Letizia Foroni1,2, Alistair Reid1,2*, Amin Rahemtulla1,2, Michael Stump6*, Irene Roberts1,2 and Anastasios Karadimitris1,2*

1Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom; 2Centre for Haematology, Imperial College London, London, United Kingdom; 3Department of Cell and Developmental Biology, University College London, London, United Kingdom; 4Department of Haematology, Theagenio Cancer Hospital, Thessaloniki, Greece; 5Department of Haematology, Aristotelion University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece; 6Centre for Bioinformatics and Institute of Mathematical Sciences, Imperial College London, London, United Kingdom; 7Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece; 8Haematology, Chelsea and Westminster Hospital NHS Trust, London, United Kingdom; 9Department of Histopathology, Hammersmith Hospital, Imperial Healthcare NHS Trust, London, United Kingdom.

Unlike the established role of acquired genetic events and bone marrow microenvironment in the pathogenesis of multiple myeloma (MM), the phenotype and function of cells enriched in tumor-propagating activity and their relationship to the phenotypic architecture in MM are controversial. Because the immunoglobulin heavy (IgH) chain class-switched myeloma plasma cell (PC) is the final event of a linear, B cell lineage developmental process, it was suggested that myeloma cell growth is sustained by a minority of cells more immature than the PC. We combined multiparametric flow-cytometry and sorting with patient-specific quantitative PCR (qPCR) to dissect the myeloma clonal organisation in the bone marrow (BM) and peripheral blood (PB). In a cohort of 30 patients we show that MM comprises at least four hierarchically organised, clonally-related sub-populations which, although phenotypically distinct, share the same oncogenic chromosomal abnormalities as well as IgH chain complementarity region 3 area sequence. We found rare CD19+ clonotypic cells with phenotype either of resting memory cell (CD19+CD38-IgD-CD27-/+) or plasmablasts (CD19+CD38++CD319+CD138-) and CD19-CD38hiCD319+CD200+CD56+ clonotypic cells, comprising CD138- (~3% of the clone, termed Pre-PC), CD138low and CD138+ PC. The clonal populations resemble their normal counterparts and exist in nearly logarithmic incremental frequencies in the BM. Using dynamic mathematical models and a Bayesian approach a Pre-PC->PC transition was predicted, outside the linear developmental process. Following intravenous injection of purified clonotypic populations into sub-lethally irradiated NSG mice, we found that both PC (in 9/12 of the injected mice, 75%) and Pre-PC (4/16, 25%) can engraft, but not the CD19+ clonotypic cells (0/10). Of note, upon engraftment both PC and Pre-PC regenerate the original CD19- hierarchy of the human BM, as predicted by mathematical modelling. In addition, Pre-PC are more quiescent and unlike PC, preferentially localize at extramedullary niches, such as the liver and spleen of the engrafted animals. Therefore, the myeloma-propagating activity is the exclusive property of a population characterized by its ability for bi-directional transition between the dominant PC and the low frequency Pre-PC. To gain insights into the molecular mechanisms underpinning this reversible phenotypic transition we used gene expression profiling of highly purified BM Pre-PC and PC (n=9). Differential expression analysis and principal component analysis clearly separate Pre-PC from PC, with 7 of 9 samples following the same expression pattern in hierarchical clustering. Functional annotation analysis using DAVID shows that Pre-PC are enriched in epigenetic regulators, including histone methyl-transferases (belonging to the Polycomb repressive complex 2 or Trithorax MLL activating complex) and de-methylases, histone acetyl-transferases and de-acetylases as well as several members of SWI/SNF chromatin remodeling complex, suggesting that epigenetic plasticity underpins the phenotypic diversification of myeloma-propagating cells. Finally, to study the clinical importance of the myeloma clonal organisation, with emphasis to clinical drug
resistance, we prospectively assessed the size of the different phenotypes in paired, pre- and post-treatment BM samples (n=8). We show that in all cases a higher proportion of Pre-PC than PC persisted after treatment suggesting that Pre-PC are clinically more drug-resistant than PC (median 10.3-fold, range 4.4-332, p=0.008). Thus, clinical drug resistance in MM is linked to reversible, bi-directional phenotypic transition of myeloma-propagating cells, likely under the orchestration of epigenetic regulators. These novel biological insights have important clinical implications in relation to assessment of minimal residual disease and development of alternative therapeutic strategies in MM.

Abstract ID#: 51950  
Password: 295177  
Title: Clinical Drug Resistance Linked to Inter-Convertible Phenotypic and Functional States of Tumor-Propagating Cells in Multiple Myeloma  
Review Category Selection: 651. Myeloma - Biology and Pathophysiology, excluding Therapy  
Preferred Presentation Format: Oral  
Submitter's E-mail Address: a.chaidos@imperial.ac.uk  
Publish only on the Blood Abstracts site: Yes  
First submission to an ASH Annual Meeting: No  
Compliance with the Declaration of Helsinki for Studies Involving Human Subjects: Agree  
Is the first author/presenter of this abstract a hematologist in training?: No  
Interim Analysis of Clinical Trial: No  
Special Consideration: No  
Keywords: Drug Resistance, Epigenetic, Myeloma  

First Author  
Presenter  
Corresponding  
Aristeidis Chaidos  
Hammersmith Hospital, Imperial College Healthcare NHS Trust  
Du Cane Road  
Department of Haematology  
London, W12 0HS  
United Kingdom  
Phone Number: 00442083831000  
Imperial College London  
Hammersmith Campus  
Centre for Haematology  
London, United Kingdom  
Phone Number: 44 (020) 83832171  
Email: a.chaidos@imperial.ac.uk  

I have relevant financial relationship(s) to disclose. No  
My presentation and/or paper will include information or discussion of off-label drug use. No  
Signed on 08/13/2012 by Aristeidis Chaidos  

Second Author  
Chris P Barnes  
University College London  
Gower Street  
Department of Cell and Developmental Biology  
London, WC1E 6BT  
United Kingdom  
Phone Number: 004420 7679 7712  
Email: christopher.barnes@ucl.ac.uk -- Will not be published
Abstract Submission/Modification Form

I have relevant financial relationship(s) to disclose. No
My presentation and/or paper will include information or discussion of off-label drug use. No
Signed on 08/13/2012 by Chris P Barnes

Third Author
Gillian Cowan
Imperial College London
Hammersmith Campus
Du Cane Road
Centre for Haematology
London,
United Kingdom
Phone Number: 044 208 383 2163
Email: g.cowan@imperial.ac.uk

I have relevant financial relationship(s) to disclose. No
My presentation and/or paper will include information or discussion of off-label drug use. No
Signed on 08/13/2012 by Gillian Cowan

Fourth Author
Philippa May
Hammersmith Hospital, Imperial College Healthcare NHS Trust
Du Cane Road
Department of Haematology
London, W12 0HS
United Kingdom
Phone Number: 00442083831000
Email: philippa.may@imperial.ac.uk -- Will not be published

I have relevant financial relationship(s) to disclose. No
My presentation and/or paper will include information or discussion of off-label drug use. No
Signed on 08/13/2012 by Philippa May

Fifth Author
Valeria Melo
Hammersmith Hospital, Imperial College Healthcare NHS Trust
Du Cane Road
Department of Haematology
London, W12 0HS
United Kingdom
Phone Number: 442083831000
Email: v.melo@imperial.ac.uk -- Will not be published

I have relevant financial relationship(s) to disclose. No
My presentation and/or paper will include information or discussion of off-label drug use. No
Signed on 08/13/2012 by Valeria Melo

Sixth Author
Evdoxia Hatjiharissi
Theagenio Cancer Hospital
Dragana
Department of Haematology
Thessaloniki,
Greece
Email: ehatjiharissi@gmail.com -- Will not be published

I have relevant financial relationship(s) to disclose. No
My presentation and/or paper will include information or discussion of off-label drug use. No
Signed on 08/13/2012 by Evdoxia Hatjiharissi

Seventh Author

Maria Papaioannou
Aristotelion University of Thessaloniki, AHEPA Hospital
DRAGANA
Department of Haematology
Thessaloniki,
Greece
Imperial College London
Hammersmith Campus
Du Cane Road
Centre for Haematology
London,
United Kingdom
Email: m.papaioannou@imperial.ac.uk

I have relevant financial relationship(s) to disclose. No
My presentation and/or paper will include information or discussion of off-label drug use. No
Signed on 08/13/2012 by Maria Papaioannou

Eighth Author

Heather Harrington
Imperial College London
South Kensington Campus
Centre for Bioinformatics and Institute of Mathematical Sciences
London, SW7 2AZ
United Kingdom
Phone Number: 004420 7589 5111
Email: heather.harrington06@imperial.ac.uk -- Will not be published

I have relevant financial relationship(s) to disclose. No
My presentation and/or paper will include information or discussion of off-label drug use. No
Signed on 08/13/2012 by Heather Harrington

Ninth Author

Helen Doolittle
Imperial College London
Du Cane Road
Centre for Haematology
London, W12 0NN
United Kingdom
Phone Number: 442083832171
Email: helen.doolittle@gmail.com -- Will not be published

I have relevant financial relationship(s) to disclose. No
My presentation and/or paper will include information or discussion of off-label drug use. No
Signed on 08/13/2012 by Helen Doolittle

Tenth Author

Evangelos Terpos
University of Athens School of Medicine
Alexandra General Hospital, 80 Vas. Sofias Avenue
Department of Clinical Therapeutics
Athens,
Greece
Phone Number: 30 (213) 2162846
Fax Number: 30 (210) 3381511
Email: eterpos@med.uoa.gr
Alternate Email: eterpos@hotmail.com -- Will not be published


4/8
I have relevant financial relationship(s) to disclose. No
My presentation and/or paper will include information or discussion of off-label drug use. No
Signed on 08/13/2012 by Evangelos Terpos

Eleventh Author

Meletios A Dimopoulos
University of Athens School of Medicine
Alexandra General Hospital, 80 Vas. Sofias Avenue
Department of Clinical Therapeutics
Athens,
Greece
Phone Number: 00302103381541
Fax Number: 003012103381511
Email: mdimop@med.uoa.gr

I have relevant financial relationship(s) to disclose. No
My presentation and/or paper will include information or discussion of off-label drug use. No
Signed on 08/13/2012 by Meletios A Dimopoulos

Twelfth Author

Saad Abdalla
Hammersmith Hospital, Imperial College Healthcare NHS Trust
Du Cane Road
Department of Haematology
London, W12 0HS
United Kingdom
Phone Number: 442083831000
Fax Number: Du Cane Road
Imperial College London
Du Cane Road
Centre for Haematology
London, W12 0NN
United Kingdom
Phone Number: 442083831000
Email: s.abdalla@imperial.ac.uk -- Will not be published
Alternate Email: philippa.may@imperial.ac.uk -- Will not be published

I have relevant financial relationship(s) to disclose. No
My presentation and/or paper will include information or discussion of off-label drug use. No
Signed on 08/13/2012 by Saad Abdalla

Thirteenth Author

Helen Yarranton
Chelsea and Westminster Hospital NHS Trust
369 Fulham Road
Haematology
London, SW10 9NH
United Kingdom
Phone Number: 004420 8746 8000
Email: helen.yarranton@chelwest.nhs.uk -- Will not be published

I have relevant financial relationship(s) to disclose. No
My presentation and/or paper will include information or discussion of off-label drug use. No
Signed on 08/13/2012 by Helen Yarranton

Fourteenth Author

Kikkeri Naresh
Hammersmith Hospital, Imperial Healthcare NHS Trust
Du Cane Road
I have relevant financial relationship(s) to disclose. No
My presentation and/or paper will include information or discussion of off-label drug use. No
Signed on 08/13/2012 by Kikkeri Naresh

Fifteenth Author

Letizia Foroni
Hammersmith Hospital, Imperial College Healthcare NHS Trust
Du Cane Road
Department of Haematology
London, W12 0NN
United Kingdom
Phone Number: 442083831000
Email: l.foroni@imperial.ac.uk

I have relevant financial relationship(s) to disclose. No
My presentation and/or paper will include information or discussion of off-label drug use. No
Signed on 08/13/2012 by Letizia Foroni

Sixteenth Author

Alistair Reid
Hammersmith Hospital, Imperial College Healthcare NHS Trust
Du Cane Road
Department of Haematology
London, W12 0NN
United Kingdom
Phone Number: 442083831000
Email: a.reid@imperial.ac.uk

I have relevant financial relationship(s) to disclose. No
My presentation and/or paper will include information or discussion of off-label drug use. No
Signed on 08/13/2012 by Alistair Reid

Seventeenth Author

Amin Rahemtulla
Hammersmith Hospital, Imperial College Healthcare NHS Trust

Du Cane Road
Department of Haematology
London, W12 0HS
United Kingdom
**Phone Number:** 442083831000
Imperial College London
Du Cane Road
Centre for Haematology
London, W12 0NN
United Kingdom
**Phone Number:** 442083831000
**Email:** a.rahemtulla@imperial.ac.uk -- Will not be published

I have relevant financial relationship(s) to disclose. No
My presentation and/or paper will include information or discussion of off-label drug use. No
Signed on 08/13/2012 by **Amin Rahemtulla**

**Eighteenth Author**

Michael Stumpf
Imperial College London
South Kensington Campus
Centre for Bioinformatics and Institute of Mathematical Sciences
London, SW7 2AZ
United Kingdom
**Phone Number:** 442075895111
**Email:** m.stumpf@imperial.ac.uk -- Will not be published

I have relevant financial relationship(s) to disclose. No
My presentation and/or paper will include information or discussion of off-label drug use. No
Signed on 08/13/2012 by **Michael Stumpf**

**Nineteenth Author**

Irene Roberts
Imperial College London
Du Cane Road
Centre for Haematology
London, W12 0NN
United Kingdom
**Phone Number:** 442083831000
Hammersmith Hospital, Imperial College Healthcare NHS Trust
Du Cane Road
Department of Haematology
London, W12 0HS
United Kingdom
**Phone Number:** 442083831000
**Email:** irene.roberts@imperial.ac.uk

I have relevant financial relationship(s) to disclose. No
My presentation and/or paper will include information or discussion of off-label drug use. No
Signed on 08/13/2012 by **Irene Roberts**

**Twentieth Author**

Anastasios Karadimitris
Imperial College London
Centre for Haematology
London,
United Kingdom
**Phone Number:** +44 (0)20 8383 8438
Hammersmith Hospital, Imperial College Healthcare NHS Trust
Du Cane Road  
Department of Haematology  
London, W12 0HS  
United Kingdom  
**Phone Number:** 442083831000  
**Email:** a.karadimitris@imperial.ac.uk

I have relevant financial relationship(s) to disclose. No  
My presentation and/or paper will include information or discussion of off-label drug use. No  
Signed on 08/13/2012 by Anastasios Karadimitris

---

If necessary, you can make changes to your abstract between now and the deadline of **Tuesday, August 14, 2012**

- To access your submission in the future, use the direct link to your abstract submission from one of the automatic confirmation emails that were sent to you during the submission.  
- Or point your browser to [ash/reminder.cgi](https://ash.confex.com/ash/2012/cop/papers/index.cgi?username=51950&password=295177) to have that URL mailed to you again. Your username/password are 51950/295177.

Any changes that you make will be reflected instantly in what is seen by the reviewers. You DO NOT need to go through all of the submission steps in order to change one thing. If you want to change the title, for example, just click "Title" in the abstract control panel and submit the new title.

When you have completed your submission, you may close this browser window.

**Tell us what you think of the abstract submittal**